MENU
AUTL
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Autolus Therapeutics (AUTL) Ownership - Who owns Autolus Therapeutics?
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
191 Wood Lane
Phone
+44 2038296230
Employees
471
Web
https://www.autolus.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
425.81M
P/E Ratio
N/A
Total Cash
657.07M
Projected Growth
N/A
Total Debt
52.23M
Revenue
10.09M
Risk (Beta)
2.26
Dividend Yield
N/A
Total Cash/Share
2.47
Total Debt/Equity
N/A
Revenue/Share
0.04 USD as % of share price
Fundamentals
AUTL
Capitalization
426M
P/E Ratio
N/A
Risk (Beta)
2.26
Dividend Yield
N/A
Total Cash
657M
Total Cash/Share
2.47
Total Debt
52.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.04%
Revenue
10.1M
ROE
N/A
Book Value
477M
P/B Ratio
0.94
Cash Flow
N/A
Earnings
-1.22
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
12K
Current Ratio
13.69
Current Revenue Per Employee
21794.82
Dividends Per Share - Security
N/A
EBITDA
-192.51M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-43.81
Shares Held By Institutions
490M
Shares Outstanding - Current
266M
Total Liabilities
351M
Total Volume MTD
N/A
Value
N/A
Gain YTD
-31.915
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
a developer of cancer treatments
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
191 Wood Lane
Phone
+44 2038296230
Employees
471
Web
https://www.autolus.com